Seffalair Spiromax contains the long-acting beta agonist (LABA) salmeterol and the inhaled corticosteroid (ICS) fluticasone. It is indicated for the regular treatment of asthma in patients not adequately controlled with ICS and 'as needed' inhaled short-acting β2 agonist.
The inhaler is available in two strengths, providing salmeterol/fluticasone propionate delivered doses of 12.75/100 microgram and 12.75/202 microgram.
The Spiromax device, which is also available as Duoresp Spiromax (formoterol/budesonide, indicated in asthma and COPD), is breath-actuated dry powder inhaler that has a design similar to that of pressurised metered-dose inhalers.
There are three steps to using the Spiromax inhaler: open, breathe and close. No priming is required. Dose confirmation is provided by a 'click' sound, lactose taste and a dose indicator.
As a dry powder inhaler, Seffalair Spiromax has a lower carbon footprint than pressurised metered dose inhalers (MDIs). MDIs have estimated carbon footprints of 500g CO2eq per dose, compared to 20g in dry powder inhalers, according to NICE. A patient decision aid published by NICE in 2019 recommends that prescribers and patients opt for the most environmentally friendly option when faced with a choice of suitable devices.